Takeda Pharmaceutical Co Ltd Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/16/2026)
| Balance Sheet | Total Assets | 15,453,113,000,000.00 | ROE | 50.30 % |
| Balance Sheet | Total Equity | 7,773,592,000,000.00 | ROA | 1.24 % |
| Cashflow | Capital Expenditures | -176,003,000,000.00 | P/FCF | 12.07 |
| Cashflow | Free Cash Flow | 762,705,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 938,708,000,000.00 | P/CF | 9.80 |
| Income | Earnings per Share (diluted) | 122.72 | Div. Yield | 3.39 % |
| Income | Net Income | 191,762,000,000.00 | P/E | 47.99 |
| Income | Shares Outstanding | 1,562,576,000.00 | P/B | 1.18 |
| Income | Total Revenue | 4,505,720,000,000.00 | P/S | 2.04 |
Ratios calculated on: 10/14/2026
Company Description
Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.takeda.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more